IEEE Rev Biomed Eng. 2014;7:143-53. doi: 10.1109/RBME.2014.2300234.
This paper discusses the reasons why evidence of clinical effectiveness is not enough to facilitate adequate adoption of robotic technologies for upper-limb neurorehabilitation. The paper also provides a short review of the state of the art technologies. In particular, the paper highlights the barriers to the adoption of these technologies by the markets in which they are, or should be, deployed. On the other hand, the paper explores how low rates of adoption may depend on communication biases between the producers of the technologies and potential adopters. Finally, it is shown that, although technology-efficacy issues are usually well-documented, barriers to adoption also originate from the lack of solid evidence of the economic implications of the new technologies.
本文讨论了为什么临床疗效证据不足以促进上肢神经康复机器人技术的充分采用。本文还对现有技术进行了简要回顾。特别是，本文强调了这些技术在其所在或应部署的市场中采用的障碍。另一方面，本文探讨了采用率低可能取决于技术生产者和潜在采用者之间的沟通偏见。最后，结果表明，尽管技术功效问题通常有充分的记录，但采用障碍也源于缺乏新技术经济影响的可靠证据。
